All articles by Amit Thadani
Amit Thadani
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine
OSLO, Norway and BILTHOVEN, Netherlands — CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI’s US$200m program to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses.
New United European Gastroenterology report reveals major health and economic impact of digestive diseases across Europe
VIENNA– Data from a new pan-European study on the burden of digestive diseases, presented today at UEG Week 2022 and published in the United European Gastroenterology Journal, highlights a worrying increase in the prevalence of several digestive diseases since 2000. These include chronic liver diseases, pancreatitis, gastroesophageal reflux disease, gastritis, vascular intestinal disorders and coeliac disease in children. In addition, the incidence and mortality rates for all digestive cancers combined have increased by 26% and 17% respectively in the period 2000-2019.
Critical Care Diagnostics Market to Exceed US$ 1.7 Billion by 2031 Amid Rising Prevalence of Chronic Diseases
Rising Expenditure in ICUs and Emergency Rooms to Push Critical Care Diagnostic Sales by 5.5%
MEDICA HEALTH IT FORUM focuses on sustainability – the value of health IT in fighting climate change
Future hybrid health networking as the ideal joining of digital processes and the “human factor”
JUNO DIAGNOSTICS ANNOUNCES APPOINTMENT OF TODD WHITSON AS EVP, GLOBAL BUSINESS DEVELOPMENT AND COMMERCIAL OPERATIONS
Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations. Mr. Whitson is a well-recognized veteran in the genetics and molecular diagnostics fields who brings more than two decades of healthcare experience to JunoDx.
Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu® (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets
Model Medicines, a pharmatech company working to transform the drug discovery and development industry using artificial intelligence (AI), today announced the launch of its oncology programs. The programs are focused on the discovery and development of therapeutics against two oncogenic and epigenetic targets – AXL and BRD4 – with applications in numerous indications, including both hematological and solid malignancies. The Company reported the discovery of several chemotypes that display nanomolar or low micromolar activity against AXL and BRD4, and which represent entirely new pharmacophores for these targets. This announcement follows the company’s Q2 2022 announcement that its AI-discovered lead compound, MDL-001, developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai, demonstrated preclinical proof-of-concept and best-in-class characteristics as a potential broad spectrum infectious disease therapeutic.
Intravacc Awarded US$14.6 Million NIH/NIAID Contract to Develop Intranasal Gonorrhea Vaccine
Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a contract with base and options that may total US$14.6 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Gonorrhea is a sexually transmitted disease caused by the NG bacteria. Intravacc will develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.
ProtonDx Awarded £365,000 Defra and Innovate UK Grant to Develop Porcine Lung Disease Diagnostic
LONDON, UK — ProtonDx Ltd, an Imperial College health technology spin-out company delivering cost-effective, ultra-rapid, accurate and portable molecular testing, has been awarded a £365,000 grant from Defra’s Farming Innovation Programme and UKRI’s Transforming Food Production Challenge (Innovate UK) to develop rapid, accurate, point-of-care tests for porcine lung diseases, in collaboration with Imperial College London.
How Healthcare Organizations Can Enhance a Holistic Patient and Member View by Improving Insights from Data
A future-proof enterprise content management and enterprise imaging strategy across healthcare organizations enables individualized experiences, cost-saving efficiencies, and productivity gains